Edition:
United States

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

19.69USD
15 Dec 2017
Change (% chg)

$-0.85 (-4.14%)
Prev Close
$20.54
Open
$20.53
Day's High
$20.79
Day's Low
$19.44
Volume
1,360,561
Avg. Vol
389,208
52-wk High
$21.08
52-wk Low
$9.69

Select another date:

Thu, Dec 7 2017

BRIEF-Alexion And Halozyme Enter License Agreement For ENHANZE Technology

* ALEXION AND HALOZYME ENTER LICENSE AGREEMENT FOR ENHANZE TECHNOLOGY Source text for Eikon: Further company coverage:

BRIEF-Halozyme reports Q3 EPS of $0.02

* Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S

BRIEF-Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex

* Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex with co's enhanze technology​

Halozyme to license drug delivery tech to Roche, Bristol-Myers

U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations.

BRIEF-Halozyme licenses new Enhanze target for $30 mln upfront payment

* Halozyme licenses new enhanze target for $30 million upfront payment, future milestones and royalties

Halozyme to license drug delivery tech to Roche, Bristol-Myers

Sept 14 U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations.

BRIEF-Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology

* Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology

BRIEF-Halozyme reports Q2 loss per share $0.23

* Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S

BRIEF-Halozyme announces initiation of clinical trial collaboration

* Initiation of clinical trial collaboration evaluating Halozyme's pegph20 in combination with anti-PDL1 immunotherapy

BRIEF-Halozyme Therapeutics, unit entered into first amendment to amended, restated lease with BMR-11388 Sorrento Valley Road

* Halozyme Therapeutics Inc - co, unit entered into a first amendment to amended and restated lease with bmr-11388 sorrento valley road lp

Select another date: